Corbus Pharmaceuticals Holdings, Inc. 0SZI.L Stock
Corbus Pharmaceuticals Holdings, Inc. Price Chart
Corbus Pharmaceuticals Holdings, Inc. 0SZI.L Financial and Trading Overview
Corbus Pharmaceuticals Holdings, Inc. stock price | 48.64 USD |
Previous Close | 8.57 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 12.85 USD |
Volume | 117 USD |
Avg. Volume | 831 USD |
Market Cap | 5.53M USD |
Beta (5Y Monthly) | 2.421478 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.312 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0SZI.L Valuation Measures
Enterprise Value | 14.38M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 2.069142 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -0.335 |
Trading Information
Corbus Pharmaceuticals Holdings, Inc. Stock Price History
Beta (5Y Monthly) | 2.421478 |
52-Week Change | -9.38% |
S&P500 52-Week Change | 20.43% |
52 Week High | 12.85 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 9.1 USD |
200-Day Moving Average | 6.24 USD |
0SZI.L Share Statistics
Avg. Volume (3 month) | 831 USD |
Avg. Daily Volume (10-Days) | 121 USD |
Shares Outstanding | 57.24M |
Float | 4.2M |
Short Ratio | N/A |
% Held by Insiders | 0.31% |
% Held by Institutions | 9.38% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor | 0.033333:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -37.0069% |
Return on Equity (ttm) | -130.52% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -16136826 USD |
EBITDA | -42866164 USD |
Net Income Avi to Common (ttm) | -50654472 USD |
Diluted EPS (ttm) | -0.312 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 44.23M USD |
Total Cash Per Share (mrq) | 10.49 USD |
Total Debt (mrq) | 24.84M USD |
Total Debt/Equity (mrq) | 150.9 USD |
Current Ratio (mrq) | 3.194 |
Book Value Per Share (mrq) | 3.905 |
Cash Flow Statement
Operating Cash Flow (ttm) | -42044056 USD |
Levered Free Cash Flow (ttm) | -21740776 USD |
Profile of Corbus Pharmaceuticals Holdings, Inc.
Country | United Kingdom |
State | MA |
City | Norwood |
Address | 500 River Ridge Drive |
ZIP | 02062 |
Phone | 617 963 0100 |
Website | https://www.corbuspharma.com |
Industry | |
Sector(s) | |
Full Time Employees | 33 |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Q&A For Corbus Pharmaceuticals Holdings, Inc. Stock
What is a current 0SZI.L stock price?
Corbus Pharmaceuticals Holdings, Inc. 0SZI.L stock price today per share is 48.64 USD.
How to purchase Corbus Pharmaceuticals Holdings, Inc. stock?
You can buy 0SZI.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Corbus Pharmaceuticals Holdings, Inc.?
The stock symbol or ticker of Corbus Pharmaceuticals Holdings, Inc. is 0SZI.L.
How many shares does Corbus Pharmaceuticals Holdings, Inc. have in circulation?
The max supply of Corbus Pharmaceuticals Holdings, Inc. shares is 68.46M.
What is Corbus Pharmaceuticals Holdings, Inc. Price to Earnings Ratio (PE Ratio)?
Corbus Pharmaceuticals Holdings, Inc. PE Ratio is now.
What was Corbus Pharmaceuticals Holdings, Inc. earnings per share over the trailing 12 months (TTM)?
Corbus Pharmaceuticals Holdings, Inc. EPS is -0.312 USD over the trailing 12 months.